Mezzion Pharmaceuticals

Focus: Mezzion Pharmaceuticals is a Seoul-based small molecule pharmaceutical company focused on neurology and cardiovascular indications. The company operates at modest scale with a clinical-stage pipeline centered on udenafil repurposing.

Neurology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Mezzion Pharmaceuticals

AI assessmentNot Hiring

No open roles listed right now. Follow Mezzion Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

4 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Udenafil

Single Ventricle Heart Disease After Fontan Surgery

Phase 1/2

Clinical Trials (1)

NCT02201342Pharmacokinetic/Pharmacodynamic Study of Udenafil in Adolescents

Phase 1/2

Help build intelligence for Mezzion Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused pipeline: 5 clinical programs across Phase 1/2 and Phase 3, all centered on udenafil in single ventricle heart disease, enabling deep specialization
Asian pharma growth: Seoul headquarters positions you in a high-growth regional biotech market with increasing global relevance
Pre-commercial inflection point: Phase 3 programs advancing toward potential regulatory milestones creates near-term career acceleration opportunity

Watch Out For

Zero current open positions and minimal hiring activity signal limited near-term career mobility or expansion
Undisclosed financials, employee count, and funding status create opacity around company stability and salary competitiveness
Narrow therapeutic focus on a single molecule limits career diversification and portfolio hedging

Generated by Claude from Mezzion Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Udenafil

Single Ventricle Heart Disease

Phase 3

Clinical Trials (1)

NCT02741115Fontan Udenafil Exercise Longitudinal Assessment Trial

Phase 3

Udenafil

Single Ventricle Heart Disease

Phase 3

Clinical Trials (1)

NCT05918211Fontan Udenafil Exercise Longitudinal Assessment Trial - 2

Phase 3

Udenafil

Functional Single Ventricle Heart Disease

Phase 3

Clinical Trials (1)

NCT03013751A Extension Study of Udenafil in Adolescents

Phase 3

Udenafil

Single Ventricle Heart Disease

Phase 3

Clinical Trials (1)

NCT03430583Evaluation of Fontan-associated Hepatic Stiffness and the Efficacy of Udenafil in Reducing Liver Stiffness

Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 5 clinical trials

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo